JW74

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

JW74 拮抗 LiCl 诱导的经典 Wnt 信号传导激活 (IC50: 420 nM)。

JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling (IC50: 420 nM).(In Vitro):Ki-67 expression is reduced from 97.5% in DMSO-treated cells to 86.7% in JW74-treated cells. Relative to DMSO-treated cells, the cellular viability of U2OS cells treated for 72 h treatment with 10 μM JW74 is reduced to 80%. The effect of tankyrase inhibition on cellular viability is tested by performing an MTS assay. Flow cytometry is also performed to determine the expression marker Ki-67 in U2OS following 48 h treatment with DMSO or 10 uM JW74 . JW74 displays a reduction of canonical Wnt signaling in the ST-Luc assay (IC50: 790 nM) .(In Vivo):The in vivo efficacy of JW74 is tested using SW480 cell xenografts. A relatively high dose of JW74 (150 or 300 mg/kg) is used because of a rapid compound degradation in the organism as indicated in the human liver microsome analysis (t1/2=2.5 minutes) and in pharmacokinetic analyses (after peroral injections: t1/2=30 minutes and intravenous injections: t1/2=15 minutes). JW74 concentration in tumors is in the range 4.2 to 72.1 μmol/kg for JW74 150 mg/kg, 1.9 to 11.1 μmol/kg for JW74 300 mg/kg, and 2.8 μM in plasma for both doses .

JW74 shows a reduction of canonical Wnt signaling in the ST-Luc assay with an IC50 of 790 nM. The effect of tankyrase inhibition on cellular viability is tested by performing an MTS assay. The cellular viability of U2OS cells treated for 72 h treatment with 10 μM JW74 is reduced to 80%, relative to DMSO-treated cells. Flow cytometry is also performed to determine the expression marker Ki-67 in U2OS following 48 h treatment with DMSO or 10 uM JW74. Ki-67 expression is reduced from 97.5% in DMSO-treated cells to 86.7% in JW74-treated cells.

The in vivo efficacy of JW74 is tested using SW480 cell xenografts. A relatively high dose of JW74 (150 or 300 mg/kg) is used because of a rapid compound degradation in the organism as indicated in the human liver microsome analysis (t1/2=2.5 minutes) and in pharmacokinetic analyses (after per oral injections: t1/2=30 minutes and intravenous injections: t1/2=15 minutes). The presence of JW74 in tumors and plasma is identified by mass spectrometry. JW74 concentration in tumors is in the range 4.2 to 72.1 μmol/kg for JW74 150 mg/kg, 1.9 to 11.1 μmol/kg for JW74 300 mg/kg, and 2.8 μM in plasma for both doses.

——

Wnt/Notch/Hedgehog

Wnt/beta/catenin

S. aureus

——

——

863405-60-1

456.52

C24H20N6O2S

>98% (HPLC)

In Vitro:?DMSO : ≥ 50 mg/mL (109.52 mM)

COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1

——

(-20℃)

With Ice Pack

≥ 2 years